Biocon has launched a biosimilar of Bevacizumab in India for treating patients with several types of cancer.
Krabeva is a monoclonal antibody which, the company said, will help expand access to a high quality biosimilar Bevacizumab for cancer patients in India.
It is the world´s first and only Bevacizumab with a unique ´QualCheck´ mechanism, Biocon said, which will ensure that patients get a quality-ascertained product right up to infusion.
Bevacizumab is indicated as a first-line treatment of patients with metastatic colorectal cancer, and is accepted as a standard treatment option in combination with chemotherapy for patients with non-small-cell lung cancer, metastatic renal cell carcinoma and recurrent ovarian cancer.
Krabeva is the second key oncologic biosimilar product from Biocon´s global biosimilars portfolio to be launched in India as part of the company’s ongoing missions to “address the unmet patient need for affordable biological therapies”.
The launch follows the successful completion of Phase III clinical trials and approval of Biocon´s Marketing Authorisation Application by the Drug Controller General of India.